Fanconi anaemia (FA) is an autosomal-recessive disorder, characterized by skeletal abnormalities, progressive bone marrow failure and cellular hypersensitivity to DNA damaging agents such as Mitomycin C. FA also increases the likelihood of cancerous tumors and childhood leukemia.
Fanconi anaemia (FA) is a known complication of cancer therapy, and the use of FANC antibodies form a routine part of cancer research. Antibody suppliers, such as Novus Biologicals, supply anti-FANC antibodies which interact with FANC proteins in Western blot analysis and similar assays.
The FANCD2 protein is of particular importance, and is activated via the interaction of several other FANC proteins in a nuclear complex. This process (known as monoubiquitination) results in the formation of FANCD2/BRCA1 nuclear foci.
The FANCD2 protein is essential for the resistance of DNA cross-linking. It is also vital for arresting DNA synthesis following exposure to ionizing radiation, meaning it plays an important role in cell repair following cancer therapy. Several studies have concentrated on the FANCD2 pathway in patient-derived Fanconi anaemia cell lines, using anti-FANC antibodies such as those in Novus Biologicals' antibody catalog.
We at Novus Biologicals cover the full range of FANC antibodies. Our antibody catalog includes FANCA, FANCB, FANCG, FANCE, FANCL, FANCM, FANCI, FANCC and FANCF antibodies, as well as FANCD2. These are used to study various elements of the D2 pathway. For example, FANCF antibodies have been used to track FANCF protein expression in human lymphoblasts, thus providing essential data on the role of FANCF in the formation of active FANCD2 foci.
